Sanctuary Advisors LLC Has $194,000 Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Sanctuary Advisors LLC reduced its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 73.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 27,924 shares of the company’s stock after selling 77,000 shares during the period. Sanctuary Advisors LLC owned approximately 0.05% of Zevra Therapeutics worth $194,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of ZVRA. Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at about $127,000. Barclays PLC increased its stake in Zevra Therapeutics by 292.6% in the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after buying an additional 42,926 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Zevra Therapeutics by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after acquiring an additional 129,600 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at about $94,000. Finally, State Street Corp increased its position in shares of Zevra Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after purchasing an additional 52,966 shares during the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA opened at $8.39 on Monday. Zevra Therapeutics, Inc. has a 1 year low of $4.20 and a 1 year high of $9.76. The company’s 50 day simple moving average is $8.74 and its 200 day simple moving average is $7.39. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The stock has a market capitalization of $447.82 million, a price-to-earnings ratio of -4.26 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. During the same quarter in the prior year, the company earned ($0.40) earnings per share. As a group, research analysts predict that Zevra Therapeutics, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ZVRA has been the topic of several analyst reports. Guggenheim initiated coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 price target on the stock. JMP Securities started coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Finally, Roth Mkm boosted their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Zevra Therapeutics currently has an average rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.